BioCryst Pharma (BCRX) Tops Q2 EPS by 14c ; Offers Guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.31 --0%
Revenue Growth %: +13.7%
Financial Fact:
Interest and other income: 109K
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +13.7%
Financial Fact:
Interest and other income: 109K
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of $0.15, $0.14 better than the analyst estimate of $0.01. Revenue for the quarter came in at $163.35 million versus the consensus estimate of $149.82 million.
GUIDANCE:
BioCryst Pharma sees FY2025 revenue of $580-600 million, versus the consensus of $608.4 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
- Trump: Iran Informed There Are No Tolls In Hormuz
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
